All Clear

AllClear is a biotechnology company and a subsidiary of Cambrian BioPharma focused on the development of next-generation senolytic therapies. The company aims to treat age-related diseases by selectively eliminating senescent cells, which accumulate with age and contribute to chronic inflammation and tissue dysfunction. Utilizing a small molecule approach, AllClear targets specific survival pathways in these cells to induce apoptosis and promote tissue regeneration. As part of the Cambrian BioPharma "PipeCo" model, the company leverages centralized resources to advance its pipeline toward clinical trials for indications such as fibrosis and metabolic disorders.